EPO to Award Alnylam Patent on Use of RNAi Molecules in Cancer | GenomeWeb

Alnylam Pharmaceuticals said this week that the European Patent Office intends to grant the company a patent covering the use of RNAi therapeutics in cancer.

The intellectual property, EP Application No 02702247.4, is derived from the so-called Kreutzer-Limmer III patent series developed by Germany’s Ribopharma, which Alnylam acquired in 2003 and later sold off to Roche (see RNAi News, 7/12/2007).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.